Welcome to our dedicated page for Aptose Biosciences news (Ticker: APTO), a resource for investors and traders seeking the latest updates and insights on Aptose Biosciences stock.
Aptose Biosciences, Inc. (NASDAQ: APTO, TSX: APS) is a clinical-stage biotechnology company dedicated to developing precision medicines for the treatment of life-threatening cancers. This science-driven organization is focused on advancing first-in-class agents targeting acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), and other hematologic malignancies. Based on a deep understanding of the genetic and epigenetic profiles of specific cancers and patient demographics, Aptose is building a robust pipeline of novel oncology therapies aimed at dysregulated processes and signaling pathways.
One of Aptose's pioneering agents, tuspetinib (TUS), is a highly potent, first-in-class pan-FLT3/BTK inhibitor. Developed as a small molecule therapeutic, tuspetinib targets various key kinases such as SYK, FLT3, JAK1/2, and mutant forms of KIT, RSK2, and TAK1-TAB1. This mechanism of action not only combats the proliferation of AML cells but also minimizes the typical cytotoxic side effects associated with conventional cancer treatments, thus enhancing the quality of life for patients.
Tuspetinib has shown significant promise in ongoing clinical trials. In the APTIVATE Phase 1/2 study, tuspetinib, both as a monotherapy and in combination with venetoclax (VEN), has demonstrated favorable safety profiles and robust efficacy in relapsed/refractory AML patients. This includes patients with various genetic mutations and those who have failed prior therapies. Notably, tuspetinib has demonstrated a 48% overall response rate when used in combination with venetoclax, making it a potential candidate for accelerated approval in difficult-to-treat VEN-resistant AML cases.
Aptose is also developing luxeptinib (CG-806), an oral, dual lymphoid and myeloid kinase inhibitor currently in Phase 1 a/b development. Luxeptinib targets relapsed or refractory hematologic malignancies and is being positioned for future clinical trials using its new generation 3 (G3) formulation, which has shown improved pharmacokinetics and tolerability.
Recently, Aptose has entered strategic financial transactions, including a public offering and private placement, to support the further development of tuspetinib and general corporate activities. With strong clinical data and robust financial backing, Aptose continues to make strides in the oncology field, aiming to bring life-saving treatments to patients in need.
Aptose Biosciences (Nasdaq: APTO; TSX: APS) will announce its financial results for Q1 2021 on May 4, 2021, after market close. The announcement will be followed by a conference call at 4:30 PM ET. Investors can access the call via dial-in or webcast. The Q1 report will include financial statements and management’s discussion available on SEDAR and EDGAR. Aptose focuses on developing therapies for unmet needs in oncology, particularly in hematology, with investigational products luxeptinib and APTO-253 undergoing clinical trials.
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS) will participate in Canaccord Genuity’s 2021 Horizons in Oncology Virtual Conference on April 15, 2021, from 3:00 to 3:55 PM EDT. CEO William G. Rice, Ph.D. will join a panel discussing opportunities in BPDCN and AML, moderated by John Newman, Ph.D.
The company focuses on developing personalized therapies for oncology, particularly hematology. Their pipeline includes luxeptinib, a mutation-agnostic FLT3/BTK inhibitor, and APTO-253, which targets the MYC oncogene.
Aptose Biosciences Inc. (NASDAQ: APTO) reported a net loss of $14.7 million for Q4 2020, increasing to $55.2 million for the full year, attributed mainly to higher R&D and stock-based compensation expenses. The company continues to progress in its clinical trials for luxeptinib and APTO-253, with encouraging early signs of anti-cancer activity. Additionally, CFO Gregory Chow is resigning, with Dr. William Rice taking over as Chief Accounting Officer. As of December 31, 2020, Aptose had $122.4 million in cash, sufficient to support operations through mid-2023.
Aptose Biosciences announces key management appointments to enhance clinical development and regulatory functions. George Melko, Pharm.D., joins as Vice President of Regulatory Affairs, bringing over 20 years of oncology regulatory experience from companies like Tmunity and Incyte. Robert Killion, Ph.D., appointed Vice President of CMC, has over 20 years in manufacturing and quality control from firms such as Gilead and Roche. These hires aim to support ongoing Phase 1 trials of CG-806 and APTO-253, reinforcing Aptose's commitment to advancing innovative cancer therapies.
Aptose Biosciences Inc. (Nasdaq: APTO) will release its financial results for the year and quarter ended December 31, 2020, on March 23, 2021, after market close. The company is focused on developing therapeutics targeting cancer mechanisms, particularly in hematology. Aptose's clinical pipeline includes CG-806, a first-in-class mutation-agnostic FLT3/BTK kinase inhibitor, and APTO-253, which directly targets the MYC oncogene. Both products are currently in clinical trials.
Aptose Biosciences has initiated dosing of the first patient in a Phase 1 a/b clinical study for CG-806, an oral kinase inhibitor targeting acute myeloid leukemia (AML). The starting dose of 450mg was selected based on previous safety and efficacy data in chronic lymphocytic leukemia (CLL) trials. This multicenter, open-label study aims to evaluate the drug's safety and pharmacodynamics in relapsed or refractory AML patients. The company is also conducting another Phase 1 study for B-cell malignancies.
Aptose Biosciences Inc. (Nasdaq: APTO) announced its participation in the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on September 22, 2020, at 1:40 PM EDT. The event will feature a fireside chat with Matthew Biegler, Senior Analyst at Oppenheimer. The audio webcast can be accessed via the Aptose website and will be archived post-event. Aptose focuses on developing targeted cancer therapeutics, including CG-806 and APTO-253, currently in clinical trials for hematologic malignancies.
Aptose Biosciences (Nasdaq: APTO; TSX: APS) has announced participation in two upcoming virtual conferences in September 2020. The H. C. Wainwright 22nd Annual Global Investment Conference is scheduled for September 14, 2020, at 2:30 PM EDT, while the Cantor Virtual Global Healthcare Conference will take place on September 17, 2020, at 10:00 AM EDT. The management team, led by Dr. William G. Rice, will present and discuss their innovative oncology therapies targeting hematologic malignancies. Webcasts are available through the Aptose website.
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) announced participation in the Canaccord Genuity 40th Annual Growth Conference from August 11-13, 2020. Key executives, including Dr. William G. Rice, will present a corporate overview and strategic direction on August 13 at 2:00 p.m. ET. The live presentation can be accessed via Webcast Link, with an archived version available for 90 days on the company's website.
Aptose Biosciences announced advancements in its clinical trials for CG-806 and APTO-253, with progress into higher dose cohorts and FDA approval for CG-806's IND in AML at a 450 mg dose. Financially, the company reported a net loss of $15.8 million for Q2 2020, up from $6.2 million YOY, primarily due to increased stock-based compensation and program costs. Cash and investments totaled $82.7 million, sufficient for operations through 2023. The company recently raised approximately $55.125 million through a public offering of common shares.
FAQ
What is the current stock price of Aptose Biosciences (APTO)?
What is the market cap of Aptose Biosciences (APTO)?
What does Aptose Biosciences specialize in?
What is tuspetinib?
What are the recent achievements of Aptose Biosciences?
What is luxeptinib?
How does Aptose aim to improve the quality of life for cancer patients?
What financial activities has Aptose recently undertaken?
What are the main clinical trials conducted by Aptose?
What makes tuspetinib a potential candidate for accelerated approval?
How does Aptose integrate genetic insights into its drug development?
What is the strategy behind Aptose's targeted therapies?
